Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
Status:
Completed
Trial end date:
2019-06-04
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the effect of 2 dose levels of TMX-049 on
urinary albumin excretion in subjects with Type 2 diabetes and albuminuria (a urinary
albumin-to-creatinine ratio (UACR) 200 to 3000 mg/g and an estimated glomerular filtration
rate (eGFR) ≥30 ml/min/1.73m2). Effects of each TMX-049 dose on UACR will be assessed in
terms of ratios using log-transformed UACR at Baseline and after a 12-week period of
treatment.